At a glance
ClinicalIndex Comparison RecordN/ACompleted· 687 enrolled
Drug / intervention
Atorvastatindrug
Likely dose
Atorvastatin 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Oct 14, 2009·Updated Feb 18, 2021
In Brief
An observational study evaluating Atorvastatin for Cardiovascular Diseases and Coronary Artery Disease. Completed, enrolled 687 participants.
Detailed Summary
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Artery Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartApr 2010
Primary CompletionDec 2011
TodayJul 2026
First PostedOct 14, 2009
Enrollment StartApr 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.7 years ago
Interventions
Atorvastatindrug
Atorvastatin, 10- 80 mg, once daily, 6 month treatment